基于HIS的药品上市后安全性再评价系统研发与应用-机械工程专业论文.docxVIP

ABSTRACTAbstract ABSTRACT Abstract With the growth of difficult and complicated diseases．the market demands for pharmaceuticals have increased，therefore，people are in the urgent need of drug safety．At present，there are various limits in the clinical study before new drugs go on sale．For example，the research of ADR for new drugs needs improving．SO it is significant to revalue drug safety after go on sale． Analysis of well．known larger amount of data analysis and simulation results closer to the true result，and leSS vast data resources currently researches on postmarketing safety evaluation after the use of data analysis application HIS system；to collect from the HIS system there are a lot of data for the study does not make sense，redundant data information； for drug safety does not have a more systematic evaluation．In this study,the above evaluation of drug safety problems in a study，the main contents include the following： First，the development of interfaces，through HIS system and adverse reactions reported docking system to achieve rapid drug re—evaluation of information collection．Then．the collected data data cleaning，sorting and other normative operations，including：remove obvious mistakes ADR reporting and clear the redundant information and correct irregularities and adverse drug names．Secondly，epidemiology and statistics used in the study of Logistic regression model was applied to the safety analysis of the drug among the factors．Finally,based on the completion of the initial application after HIS drug marketing safety re．evaluation of the design and development of the system．and carried out． Aiming at the blemish and disadvantage of Our country’S drug safety revaluatioll．the thesis research and develop a system of drug safety revaluation after go on sale．Some functions such as reporting the drug revaluation report and drug safety evaluation Can be achieved by collecting the information in the HIS of collaborative sentinel hospital．It has made positive expl